NEW YORK (AP) — Theranos Inc. named a new vice president in charge of regulatory issues and a new chief compliance officer weeks after federal regulators banned the company’s founder and CEO from owning or running a medical laboratory for two years.
The ban followed months of investigation by government testing regulators where they found a number of violations of federal testing standards at the blood-test company’s site. The action followed stories by The Wall Street Journal in which former employees said the company’s tests were unreliable.
Theranos named Dave Wurtz as vice president of regulatory and quality and it named Daniel Guggenheim, as its chief compliance officer.
They report to CEO Elizabeth Holmes.